| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Research and development | 35,052 | |||
| General and administrative | 14,129 | |||
| Total operating expenses | 49,181 | |||
| Loss from operations | -49,181 | |||
| Interest income | 3,444 | |||
| Income from transition services agreements | 1,010 | |||
| Change in fair value of participation right liability | 0 | |||
| Other income (expense) | -30 | |||
| Total other income (expense), net | 4,424 | |||
| Net loss | -44,757 | |||
| Basic net income per ordinary share | -1.03 | |||
| Diluted net income per ordinary share | -1.03 | |||
| Weighted-average shares outstanding basic | 43,491,085 | |||
| Weighted-average shares outstanding diluted | 43,491,085 | |||
BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc. (BBOT)